Search

Multisystem Inflammatory Syndrome in Children (MIS-C), a rare condition, has been reported approximately 2-4 weeks after the onset of COVID-19 in children and adolescents, causing inflammation in multiple systems, including cardiovascular and respiratory, digestive, and central nervous systems. This condition is also known as hyperinflammatory shock, Kawasaki-like disease, and Pediatric Inflammatory Multisystem Syndrome (PIMS). The signs and symptoms include but are not limited to fever, rash, peripheral edema, gastrointestinal symptoms, conjunctivitis, and shock. Thirty-eight studies met our criteria, with a total of 5822 patients. The most affected population was between 5-18 years of age. We noted that MIS-C presented with a wide range of signs and symptoms that overlap with Kawasaki Disease, including high fever, sore throat, malaise, tachypnea, tachycardia, conjunctival injection, mucosal edema, cardiac involvement, and gastrointestinal symptoms. It causes an increase in IL-17A, IL-6, and arterial damage, a distinct difference from Kawasaki disease. The laboratory findings in MIS-C showed an increase in inflammatory markers like CRP, ESR, ferritin, leukocytes, and TNF-α. WHO stated that 23% of affected children with MIS-C had underlying conditions like chronic lung diseases, cardiovascular disease, and immunosuppression. In most affected children, aspirin and IVIG were successful, which resulted in a decrease in the inflammatory markers. We find that MIS-C is a rare, but potentially fatal pediatric complication, after COVID-19 infection. The aim of this article is to study the emerging relationship between COVID-19 and MIS-C in children and adolescents affected by this condition, to discuss the immunological mechanisms, and explore potential therapies.

Objective:To optimize and develop Bi layered floating tablet (SFMS) containing ulcer protective Sucralfate as immediate release layer and anti hypertensiveMetoprolol Succinate as sustained release layer. Method: 15 formulations of Sucralfate and 10 formulations of Metoprolol Succinate is taken. By changing the concentration of Superdisintigrant, Surfectants, Alkalizing agents & Binding agents of Sucralfate and changing concentrations of Alkalizing agents and Polymers of Metoprolol Succinate the OSFMS (Optimized Sucralfate and Metoprolol Succinate Formulation) is generated.. Result: Within 5 minutes in acidic medium , 7% Superdisintigant (Crosspovidone), 7% Surfectant (Polysorbate-80), 15% Alkalizing agents(Sodium bicarbonate), 5% HPC (Binding agent) averagely produce 68.56%drug release. Within 20 hours in acidic medium , 30% Alkalizing agents(Sodium bicarbonate) , 50% Soluablepolymer (HPMC K) ,40% Polymer (Udragid RSPO, 35% HPC Polymer(NaCMC), 30% Polymer (Sodiumalginate) ,25% Polymer (HPC) , 20% Polymer, Udragid RS), 5% HPC Polymer (PVPK) produce averagely100.06% drug release. Conclusion:The optimized formulation 400 mg tablet weight of OSFMS (Optimized Sucralfate and Metoprolol Succinate Formulation) produce better result and identified as better formulation for further studies.

Objective: The present study based upon the preparation and in vitro evaluation of optimized Bi layered floating tablet (OSFMS)having tablet weight of 400 mg.(214.88 mgofsucralfate& 186 mg of Metoprol succinate). Method: Selection of the formulation, pre compression study, preparation of tablet and in vitro evaluation of tablet. Result: In presence of Lactose MFL, MCC PH 101, Sodium Bicarbonate, Polysorbate 80, Cross povidone of majore amount in Sucralfate layer and in presence of HPMC K 100 M, Sodium Bicarbonate, Eudragit RSPO, Na CMC ,Sodium alginate, HPC, Ethyl Cellulose of majore amount in Metoprolol Succinate layer it produce (OSFMS)tablet having weight of 400 mg.(214.88 mgofSucralfate& 186 mg of Metoprol succinate) produced average drug release 99.92 % and DT of Sucralfate was 1.04 min at acid medium of stomach and TFT of Metoprol Succinate at upper intesine was > 24hours. Conclusion: The optimized formulation of Sucralfate and Metoprolol Succinate (OSFMS) may be considered as a better formulation as Gastro Retaintive Drug Delivery System..

Key words: Corynebacterium pseudodiphtheriticum,bacteremia